Form 4: Director Birgitte Volck Acquires 6,500 Shares of Soleno Therapeutics Inc. (SLNO) as Restricted Stock Units

Director Birgitte Volck reported the acquisition of 6,500 shares of Soleno Therapeutics Inc. as restricted stock units (RSUs) on June 6, 2024.

Summary

• On June 6, 2024, Birgitte Volck, a director of Soleno Therapeutics Inc. (SLNO), acquired 6,500 shares of common stock in the form of restricted stock units (RSUs).
• The RSUs were acquired at a price of $0.
• Following the transaction, Volck directly owns 13,545 shares of Soleno Therapeutics Inc., some of which are also RSUs.
• The RSUs vest on the earlier of June 6, 2025, or the day before the next annual stockholder meeting, contingent upon continued service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares by a director is generally viewed as a positive sign, indicating confidence in the company's prospects. However, it's a routine transaction related to compensation.

Positives

• The acquisition of RSUs by a director signals confidence in the company's future.

Future Outlook

The vesting of the RSUs is contingent upon continued service, aligning the director's interests with the company's long-term performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates a director's acquisition of company stock, which can be interpreted as a positive signal.

Stakeholder Impact

• The acquisition of shares by a director can positively influence shareholder sentiment.

Key Dates